Saturday, July 11, 2026

Drug profile · INN

osilodrostat

osilodrostat (ISTURISA) is a cytochrome p450 11b1 inhibitor. Associated with Recordati Rare Diseases Australia Pty..

EMA: approved TGA: approved Systemic hormonal preparations (H02) H02CA02
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — osilodrostat
Class
Systemic hormonal preparations (H02)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

osilodrostat (ISTURISA) is a cytochrome p450 11b1 inhibitor. Associated with Recordati Rare Diseases Australia Pty..

Key facts

INN osilodrostat
Brand ISTURISA
Mechanism Cytochrome P450 11B1 inhibitor
Therapeutic class Systemic hormonal preparations (H02)
ATC code H02CA02

Mechanism of action

Cytochrome P450 11B1 inhibitor

Approval history

Authority Status Date
EMA approved
TGA approved

Pipeline programs

  1. CLCI699C2203 Phase 2 · Recordati Ireland · Cushing's disease
  2. Osilodrostat Phase 2 · Novartis India · Cushing's Syndrome
  3. Osilodrostat (Isturisa) Approved · Ultragenyx UK · Mild Autonomous Cortisol Secretion (MACS)

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is osilodrostat?

osilodrostat (ISTURISA) is a cytochrome p450 11b1 inhibitor. Associated with Recordati Rare Diseases Australia Pty..

What is the brand name for osilodrostat?

ISTURISA is a marketed brand name for osilodrostat. Check FDA Drugs@FDA for the current US label holder and prescribing information.